1. Scrip
  2. >>Business
  3. >>Deals

Alumis To Merge With Acelyrin, But Pause Lonigutamab Program

 
• By Alaric DeArment

Alumis said it will pause the planned Phase III program for Acelyrin’s lead drug and assess the value of the candidate, which produced underwhelming Phase II results in January.

(Shutterstock)

Alumis stands to bulk up its financial position as well as its portfolio of drugs to treat immune-mediated diseases through its merger with Acelyrin. But while analysts saw the deal as a positive from a financial standpoint, management comments about Acelyrin’s lead product candidate, lonigutamab, created uncertainty about the drug’s future as the company said it would look to analyze the program’s value instead of immediately going ahead with a Phase III study.

The two companies announced 6 February that they would merge in an all-stock transaction in which Acelyrin shareholders will receive 0

Key Takeaways
  • Alumis is merging with Acelyrin, creating a well-capitalized inflammation- and immunology-focused company with a TYK2 inhibitor already in late-stage development.
  • Analysts praised the all-stock deal, pointing to how it would help advance clinical programs, boost Alumis’s cash holdings and provide a win-win for shareholders

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.